Internal Medicine Alert – January 15, 2025
January 15, 2025
View Issues
-
A New Treatment for Heart Failure with Preserved Ejection Fraction
A recent randomized, placebo-controlled trial of the long-acting glucagon-like peptide-1 receptor agonist tirzepatide in patients with heart failure with preserved left ventricular ejection fraction who have obesity, diabetes, and one other weight-related comorbidity has shown that tirzepatide reduces both the symptoms of heart failure as well as the incidence of worsening heart failure events.
-
Wildfire Smoke Exposure Is a Risk Factor for Dementia
In this large, open cohort study based on electronic health record data from 2009 to 2019 of dementia-free people older than 60 years of age, exposure to wildfire smoke was shown to result in an increased incidence of dementia later in life.
-
Oseltamivir for Adults Hospitalized with Influenza: Earlier Is Better
A multicenter observational study on adults hospitalized with influenza found that initiation of oseltamivir on the day of admission reduced the risk of disease progression, including pulmonary and extra-pulmonary organ failure and death.
-
Revumenib Tablets (Revuforj)
The U.S. Food and Drug Administration has approved the first menin inhibitor, revumenib, for the treatment of relapsing or refractory acute leukemia with a lysine methyltransferase 2A gene (also known as the mixed lineage leukemia gene) translocation in adults and pediatric patients.
-
Flank Pain and ‘Heartburn?’
The electrocardiogram (ECG) in the figure was obtained from a man in his 60s who presented to the emergency department for a suspected kidney stone. The patient also noted some intermittent heartburn in recent weeks. How would you interpret his ECG? Should you activate the cath lab?